Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

Authors

Zachary A. Stacy, St. Louis College of Pharmacy, Cardiology, Mercy Hospital St. Louis, St. Louis, MO, USA. zstacy@stlcop.edu.
William B. Call, St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA.
Aaron P. Hartmann, St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA.
Golden L. Peters, St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA.
Sara K. Richter, St. Louis College of Pharmacy, Ambulatory Care, VA St. Louis Health Care System-John Cochran Division, St. Louis, MO, USA.

Document Type

Article

Publication Title

Cardiology and therapy

Abstract

Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative.

First Page

1

Last Page

18

DOI

10.1007/s40119-016-0058-2

Publication Date

6-1-2016

Recommended Citation

Stacy, Zachary A.; Call, William B.; Hartmann, Aaron P.; Peters, Golden L.; and Richter, Sara K., "Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism" (2016). Pharmacy Practice Faculty Publications. 565. https://doi.org/10.1007/s40119-016-0058-2
https://collections.uhsp.edu/pharm-practice_pubs/565